For people living with multiple myeloma, modern medicine has delivered something once unthinkable: years of disease control, thanks to continuous therapy, maintenance regimens after stem-cell transplantation, and a fast-growing arsenal of immunotherapies. But that progress has a hidden price tag. Every cycle of treatment, every hospital admission, and every follow-up appointment adds up to a life increasingly organized around the clinic. A new study from University Hospital Würzburg in Germany now offers one of the most detailed portraits yet of how patients themselves weigh that burden—and the results challenge some simple assumptions about what cancer patients really want from their care.
The research, published in Supportive Care in Cancer, surveyed 100 patients with confirmed multiple myeloma at the German tertiary center over a 12-month period. Using a mixed-methods design, the team combined structured questionnaires with free-text narratives, then integrated the two strands to see where they agreed, complemented each other, or diverged. The central concept under investigation was the treatment-free interval, or TFI: a stretch of time between active anti-myeloma treatment contacts during which no scheduled anti-myeloma therapy is given. Crucially, the researchers were careful to define TFIs as periods that could still include monitoring visits, laboratory tests, supportive-care contacts, and urgent reassessment—so a treatment-free interval is not the same as going off the radar.
The headline finding is striking. Nearly half of the participants—49 of 100, or 49.0 percent—rated the importance of intervals between inpatient treatments at the maximum of 10 on a 10-point scale, while only 9 percent rated them at zero. When patients explained in their own words why these breaks mattered, a consistent picture emerged: physical and emotional recovery, reconnecting with family, restoring daily routines, social activities, travel, and a sense of autonomy. For many respondents, the hospital was not simply a place of healing but an environment that displaced them from their own lives. The median self-reported number of inpatient days in the preceding year was 31, meaning that for a typical patient in this cohort, an entire month had been spent inside the hospital.
What made hospital stays so stressful? The most frequently cited stressor was separation from family, reported by 27 percent of participants. Treatment-related symptoms and side effects came next at 23 percent, followed by fatigue at 17 percent, food quality at 15 percent, waiting times at 14 percent, and shared rooms at 12 percent. Communication gaps, climate control problems, and lack of physical activity rounded out the list. These are, in many respects, modifiable factors—details of the care process rather than the disease itself—and they point toward concrete improvements that hospitals could implement without touching a single treatment protocol.
The ripple effects of treatment encounters extended far beyond the ward. One third of participants reported difficulties managing their households, often because of frequent admissions, cognitive strain, or stress, although two thirds managed to avoid major backlogs through planning, delegation, and online tools. Social relationships suffered for 32 percent of respondents, mainly through cancelled plans, infection precautions, and exhaustion. Among the 42 participants who were not retired or early retired, more than half—54.8 percent—reported work-related or role-related limitations, with flexible scheduling and supportive workplace policies described as key mitigating factors. The picture that emerges is of an illness whose treatment footprint touches nearly every domain of daily life.
Yet the study’s most nuanced finding concerns monitoring. While patients clearly valued breaks from active treatment, they did not want to lose touch with their medical team. Regular check-ups were described as reassuring by 77 percent of participants and as burdensome by only 13 percent, with the remainder undecided or neutral. In the qualitative narratives, this reassurance was tied to predictable scheduling, clear communication, and rapid access to the clinic when symptoms appeared. In other words, valuing intervals between treatments and valuing continued follow-up were not mutually exclusive—patients wanted both breathing room and a safety net.
Relapse anxiety, meanwhile, proved to be a powerful counterweight. Only 7 of 100 participants explicitly said they would accept a higher relapse risk in exchange for longer treatment-free intervals. This small minority stands in sharp contrast to the majority, for whom the fear of the myeloma returning outweighed the appeal of extended breaks. Preferred minimum interval lengths were similarly heterogeneous: among 99 respondents, 39.4 percent preferred intervals longer than eight weeks, 23.2 percent preferred less than four weeks, and 19.2 percent fell in the four-to-eight-week range, with 18.2 percent leaving the question unspecified. The explanations patients gave referenced recent treatment intensity, recovery needs, travel logistics, family and work responsibilities, relapse anxiety, and personal circumstances—a reminder that there is no single schedule that fits all.
The timing of this research is significant because the therapeutic landscape of multiple myeloma is changing in ways that make treatment-free intervals newly relevant. Finite-course therapies such as CAR T-cell therapy can create prolonged periods without scheduled anti-myeloma drug administration in responding patients, with long-term remission data now available for products like ciltacabtagene autoleucel and idecabtagene vicleucel. Bispecific antibodies are also increasingly being delivered through outpatient step-up dosing pathways, and prophylactic tocilizumab has been shown to reduce, though not eliminate, cytokine release syndrome during teclistamab initiation. But the authors are emphatic that finite-course treatment should not be equated with low-burden or low-risk care. CAR T-cell therapy carries risks including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias, infections, hypogammaglobulinemia, delayed neurological syndromes, and rare fatal complications, and patients still require surveillance, prophylaxis, immunoglobulin replacement, and supportive-care visits.
The study’s limitations deserve honest acknowledgment. It was a single-center, cross-sectional survey at an academic hospital, so its findings may not generalize to community settings or health systems where care is delivered differently—indeed, some treatments that require admission in Germany are handled on an outpatient basis elsewhere. The number of patients approached and reasons for nonparticipation could not be reconstructed, so a participation rate could not be calculated and nonresponse bias cannot be assessed. The self-reported inpatient-day item was not validated against administrative records, and its wording may not have consistently excluded outpatient or day-case encounters. Current regimen, administration route, treatment line, response status, cytogenetic risk, and minimal residual disease status were not captured in sufficient detail for treatment-specific analysis, and the study-specific questionnaire did not undergo formal psychometric validation. Some archived summary values did not reconcile with the cohort denominator and were omitted rather than imputed—a transparency measure that reflects the team’s methodological caution.
What the study ultimately delivers is a descriptive foundation, not a prescription. The authors explicitly state that their findings do not establish the safety or clinical appropriateness of longer treatment-free intervals and should not be interpreted as support for interrupting evidence-based therapy, which remains central to myeloma care. Lenalidomide maintenance after autologous stem-cell transplantation, for example, has demonstrated progression-free and overall survival benefits in meta-analyses. But the research does make a compelling case for preference-sensitive scheduling: prospective multicenter studies should now examine how patient goals, treatment burden, disease risk, care setting, and monitoring preferences can be woven into follow-up models whose safety and feasibility are rigorously evaluated. In the meantime, the patient-generated improvement proposals—single rooms and quieter conditions, better food, shorter waits, flexible appointments, adequate staffing, empathetic communication, and access to physiotherapy, yoga, or light exercise—offer hospitals an immediately actionable agenda. For a disease in which patients may live many years with treatment, the message from Würzburg is clear: how care is delivered matters almost as much as what is delivered, and the patients best positioned to judge that are the ones living it.
Subject of Research: Patient preferences for treatment-free intervals, monitoring trade-offs, and supportive care in multiple myeloma
Article Title: Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements
Article References: Fleischer, A., Barakat, M., Peter, J., Kadel, S.-K., Riedhammer, C., Strunz, P.-P., Mersi, J., Waldschmidt, J., Kortüm, K. M., Einsele, H., Maatouk, I., & Rasche, L. (2026). Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements. Supportive Care in Cancer, 34(10), Article 1050. https://doi.org/10.1007/s00520-026-11255-z
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11255-z
Keywords: multiple myeloma, treatment-free intervals, patient preferences, monitoring, supportive care, mixed-methods survey, CAR T-cell therapy, bispecific antibodies, lenalidomide maintenance, hospitalization burden, relapse risk, outpatient follow-up
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (October 4, 2026). Myeloma Patients Crave Breaks From Treatment but Keep Their Check-Ups. Scienmag. https://scienmag.com/myeloma-patients-crave-breaks-from-treatment-but-keep-their-check-ups/
Nathaniel Bowman. “Myeloma Patients Crave Breaks From Treatment but Keep Their Check-Ups.” Scienmag, 4 October 2026, https://scienmag.com/myeloma-patients-crave-breaks-from-treatment-but-keep-their-check-ups/. Accessed 4 October 2026.
Nathaniel Bowman. “Myeloma Patients Crave Breaks From Treatment but Keep Their Check-Ups.” Scienmag. October 4, 2026. https://scienmag.com/myeloma-patients-crave-breaks-from-treatment-but-keep-their-check-ups/
Copy citation
Download RIS
Tags: balancing treatment and life quality in myeloma patientsbispecific antibodiesCAR-T Cell Therapychallenges of ongoing cancer treatmenthealthcare organization around multiple myeloma managementhospitalization burdenimmunotherapy and maintenance regimens in myelomaimpact of continuous therapy on quality of lifelenalidomide maintenancemixed-methods research in oncologymixed-methods surveymonitoringMultiple Myelomamultiple myeloma treatment burdenoutpatient follow-uppatient perspectives on cancer care and follow-uppatient preferencespatient preferences for treatment breakspatient-reported outcomes in multiple myelomarelapse riskrole of monitoring visits during treatment pausessupportive caretreatment-free interval in myelomatreatment-free intervals
